Stonehouse Jon P — SEC insider filings
SEC reporting owner CIK 1385496. 33 insider filings on record with FilingPulse; latest filed 2026-09-02.
Transaction summary — filings shown
Covers all 33 filings on record, filed 2020-12-07 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 30,000 shares, $166,500 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 6 legs across 5 filings — 729,951 shares, $8,928,161 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 68.
- Largest priced transaction: sale of 214,917 shares @ $13.00 ($2,793,921) in BIOCRYST PHARMACEUTICALS INC, filed 2022-12-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INC (BCRX) | Director | 23 | 1 leg · 30,000 sh · $166,500 | 6 legs · 729,951 sh · $8,928,161 | 54 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) | Director | 8 | — | — | 10 |
| Metsera, Inc. (MTSR) | Director | 2 | — | — | 4 |
Insider filings — Stonehouse Jon P
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 644 @ $9.70 | EDGAR |
| 2026-06-15 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 631 @ $8.91 | EDGAR |
| 2026-03-03 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 421 @ $8.75 · Option exercise (M): 305,995 @ $3.22 · Disposition to issuer (D): 305,995 @ $8.64 · Option exercise (M): 305,995 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Tax withholding (F): 61,793 @ $7.41 | EDGAR |
| 2025-12-19 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Gift (G): 20,000 @ $0 · Gift (G): 10,000 @ $0 · Gift (G): 10,000 @ $0 | EDGAR |
| 2025-12-16 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Tax withholding (F): 27,368 @ $7.57 | EDGAR |
| 2025-11-13 | 4 | Metsera, Inc. (MTSR) | Disposition to issuer (D): 2,688 · Grant/award (A): 2,688 (derivative) · Disposition to issuer (D): 47,730 (derivative) | EDGAR |
| 2025-04-30 | 4 | Metsera, Inc. (MTSR) | Grant/award (A): 47,730 (derivative) @ $19.81 | EDGAR |
| 2024-12-23 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 362,100 @ $0 · Tax withholding (F): 14,010 @ $7.39 · Gift (G): 20,000 @ $0 · Gift (G): 10,000 @ $0 · Gift (G): 10,000 @ $0 · Grant/award (A): 750,250 (derivative) @ $0 | EDGAR |
| 2024-12-17 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Tax withholding (F): 27,525 @ $7.53 | EDGAR |
| 2024-05-15 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Purchase (P): 30,000 @ $5.55 | EDGAR |
| 2024-01-04 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Gift (G): 20,000 @ $0 · Gift (G): 10,000 @ $0 · Gift (G): 10,000 @ $0 | EDGAR |
| 2023-12-20 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Tax withholding (F): 14,089 @ $6.05 | EDGAR |
| 2023-12-18 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 127,500 @ $0 · Tax withholding (F): 13,592 @ $6.43 · Grant/award (A): 595,000 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Gift (G): 25,000 @ $0 | EDGAR |
| 2023-03-23 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Option exercise (M): 31,055 @ $3.22 · Option exercise (M): 31,055 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Gift (G): 10,000 @ $0 · Gift (G): 5,000 @ $0 · Gift (G): 5,000 @ $0 · Option exercise (M): 100,000 @ $5.45 · Sale (S): 100,000 @ $10.38 · Option exercise (M): 100,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | BELLICUM PHARMACEUTICALS, INC (BLCM) | Option exercise (M): 121,452 @ $0 | EDGAR |
| 2023-01-04 | 4/A | BELLICUM PHARMACEUTICALS, INC (BLCM) | Option exercise (M): 60,580 @ $0 | EDGAR |
| 2022-12-21 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 127,500 @ $0 · Grant/award (A): 595,000 (derivative) @ $0 | EDGAR |
| 2022-12-19 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Sale (S): 14,100 @ $10.90 | EDGAR |
| 2022-12-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Option exercise (M): 214,917 @ $1.42 · Sale (S): 214,917 @ $13 · Option exercise (M): 82,656 @ $1.42 · Sale (S): 82,656 @ $12.80 · Option exercise (M): 214,917 (derivative) @ $0 · Option exercise (M): 82,656 (derivative) @ $0 | EDGAR |
| 2022-09-02 | 4 | BELLICUM PHARMACEUTICALS, INC (BLCM) | Option exercise (M): 60,580 @ $0 | EDGAR |
| 2022-09-01 | 4/A | BELLICUM PHARMACEUTICALS, INC (BLCM) | Option exercise (M): 21,054 @ $0 · Option exercise (M): 21,054 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | BELLICUM PHARMACEUTICALS, INC (BLCM) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2022-01-13 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Option exercise (M): 184,000 @ $4.73 · Sale (S): 184,000 @ $15.04 · Option exercise (M): 184,000 (derivative) @ $0 | EDGAR |
| 2022-01-06 | 4 | BELLICUM PHARMACEUTICALS, INC (BLCM) | Option exercise (M): 21,504 @ $0 · Option exercise (M): 21,504 (derivative) @ $0 | EDGAR |
| 2021-12-16 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Gift (G): 5,000 @ $0 · Gift (G): 5,000 @ $0 · Gift (G): 5,000 @ $0 · Gift (G): 5,000 @ $0 · Grant/award (A): 123,000 @ $0 · Grant/award (A): 574,500 (derivative) @ $0 | EDGAR |
| 2021-07-07 | 4 | BELLICUM PHARMACEUTICALS, INC (BLCM) | Grant/award (A): 6,500 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | BELLICUM PHARMACEUTICALS, INC (BLCM) | Grant/award (A): 21,054 (derivative) @ $0 | EDGAR |
| 2020-12-17 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Option exercise (M): 134,278 @ $4.15 · Sale (S): 134,278 @ $8.32 · Option exercise (M): 134,278 (derivative) @ $0 · Grant/award (A): 870,000 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 157,250 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1385496 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs